17,261 trials
Hodgkin Lymphoma
Primary: Progression-Free Survival According to the Cheson Criteria by Kaplan-Meier Analysis Following Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin…
Kidney Transplantation
Primary: Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) Episode 6 Months Post-Transplant — 9; 11; 7 participants
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 63; 42 percentage of participants with response
Lymphoma, Large-Cell, Diffuse · Lymphoma, B-Cell
Primary: Number of Patients Who Achieved Complete Response — 32 participants
Methamphetamine Dependence · Substance Abuse · Methamphetamine Abuse
Primary: Change in MA Positive Urine Drug Screens Among Participants Randomly Assigned to Receive Varenicline Versus Placebo. — 7.4; 2.3 total MA-free urine drug screens
Huntington Disease · Chorea · Executive Dysfunction
Primary: Executive Function Composite Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort. — 0.005; 0.172 units…
Carcinoma, Small Cell · Lung Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 19.6 percentage of participants
Metastatic Pancreatic Cancer
Primary: Six-Month Overall Survival (OS) Probability, the Percentage of Patients Estimated to be Alive Six Months After Beginning Protocol Treatment — 37 percentage of participants
Irritable Bowel Syndrome
Primary: Colonic Compliance at Pressure at Half-Maximum Volume (Pr 1/2) — 17.57; 16.2; 18.76 mL/mm Hg
Pancreatic Cancer
Primary: Determination of Maximum Tolerated Dose (MTD), The Dose of Study Drug(s) Which Causes <33% of Patients Treated to Experience Unacceptable Side Effects — 10; 1000…
Heart Failure
Primary: Change in Serum Potassium — 0.15; 0.05 mg/dl
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the 3 Fluarix Vaccine Strains. — 22.2; 21.6; 173.8; 176.9 titers
Chronic Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1 participants
Sarcoma
Primary: Occurrence of Severe Toxicity — 1; 1 participants
Hemoglobinopathies · Sickle Cell Disease · Thalassemia
Primary: Stable Engraftment With Donor Stem Cells in Patients With Severe Hemoglobinopathy. — 2 participants